Literature DB >> 31407359

Severe maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged hospitalisation and death.

Susie Dzakpasu1, Paromita Deb-Rinker1, Laura Arbour2, Elizabeth K Darling3, Michael S Kramer4, Shiliang Liu1, Wei Luo1, Phil A Murphy5, Chantal Nelson1, Joel G Ray6, Heather Scott7, Michiel VandenHof7, K S Joseph8.   

Abstract

BACKGROUND: There is no international consensus on the definition and components of severe maternal morbidity (SMM).
OBJECTIVES: To propose a comprehensive definition of SMM, to create an empirically justified list of SMM types and subtypes, and to use this to examine SMM in Canada.
METHODS: Severe maternal morbidity was defined as a set of heterogeneous maternal conditions known to be associated with severe illness and with prolonged hospitalisation or high case fatality. Candidate SMM types/subtypes were evaluated using information on all hospital deliveries in Canada (excluding Quebec), 2006-2015. SMM rates for 2012-2016 were quantified as a composite and as SMM types/subtypes. Rate ratios and population attributable fractions (PAF) associated with overall and specific SMM types/subtypes were estimated in relation to length of hospital stay (LOS > 7 days) and case fatality.
RESULTS: There were 22 799 cases of SMM subtypes (among 1 418 545 deliveries) that were associated with a prolonged LOS or high case fatality. Between 2012 and 2016, the composite SMM rate was 16.1 (95% confidence interval [CI] 15.9, 16.3) per 1000 deliveries. Severe pre-eclampsia and HELLP syndrome (514.6 per 100 000 deliveries), and severe postpartum haemorrhage (433.2 per 100 000 deliveries) were the most common SMM types, while case fatality rates among SMM subtypes were highest among women who had cardiac arrest and resuscitation (241.1 per 1000), hepatic failure (147.1 per 1000), dialysis (67.6 per 1000), and cerebrovascular accident/stroke (51.0 per 1000). The PAF for prolonged hospital stay related to SMM was 17.8% (95% CI 17.3, 18.3), while the PAF for maternal death associated with SMM was 88.0% (95% CI 74.6, 94.4).
CONCLUSIONS: The proposed definition of SMM and associated list of SMM subtypes could be used for standardised SMM surveillance, with rate ratios and PAFs associated with specific SMM types/subtypes serving to inform clinical practice and public health policy.
© 2019 The Authors. Paediatric and Perinatal Epidemiology Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  maternal mortality; severe maternal morbidity; surveillance

Mesh:

Year:  2019        PMID: 31407359      PMCID: PMC7383693          DOI: 10.1111/ppe.12574

Source DB:  PubMed          Journal:  Paediatr Perinat Epidemiol        ISSN: 0269-5022            Impact factor:   3.980


Study question

To define severe maternal morbidity (SMM), to create an empirically justified list of SMM types and subtypes, and to use this list to examine SMM rates in Canada.

What is already known

Previous lists of SMM components exclude some important SMM types and subtypes and include some SMM types and subtypes that do not reflect severe morbidity.

What this study adds

SMM is defined as a set of heterogeneous maternal conditions known to be associated with severe illness and prolonged hospitalisation or high case fatality A set of severely morbid maternal conditions was identified based on a priori clinical knowledge, prolonged length of hospital stay, high case fatality, and expert consensus, and this should help improve surveillance and benchmarking of SMM in Canada and other high‐income countries.

INTRODUCTION

Substantial changes in maternity care were introduced in industrialised countries in the middle decades of the 20th century, including improvements in the organisation of obstetric services and widespread use of antibacterial agents, ergometrine, and blood transfusion.1, 2, 3 The substantial reduction in maternal mortality that followed led to a perception that pregnancy and childbirth had become safe and mostly risk‐free. However, maternal mortality remains a concern among vulnerable subpopulations even in high‐income countries, and severe maternal morbidity (SMM) is recognised to affect an important fraction of women.3, 4, 5, 6, 7 Although maternal death represents a more extreme and serious outcome than severe maternal illness, its rarity resulted in SMM becoming an important focus for public health surveillance and epidemiologic investigation in high‐income countries.3, 6, 7, 8 Recent changes in maternal characteristics in such countries, including increases in age and pre‐pregnancy weight, have raised new concerns about temporal trends in SMM.9, 10 Reviews of SMM cases show that, as with maternal death, the most common preventable factor is suboptimal care, including failures in diagnosis and delays in treatment.11, 12, 13, 14 The World Health Organization has recommended that maternal health surveillance focus not only on maternal mortality but also on severe acute maternal morbidity, in order to identify priorities for intervention.15 The World Health Organization defines severe maternal complications as ‘potentially life‐threatening conditions’, maternal near‐miss as ‘a woman who nearly died but survived a complication that occurred during pregnancy, childbirth or within 42 days of termination of pregnancy’, and severe maternal outcomes as maternal near‐miss cases and maternal deaths (per WHO terminology, severe acute maternal morbidity is synonymous with maternal near‐miss).15, 16 The WHO definition of near‐miss (or severe acute maternal morbidity) notwithstanding, there is little international consensus on the components of SMM, and studies on SMM typically include variable lists of maternal diseases, interventions, and organ failure types (without clear specification of how these meet a prespecified definition).4, 5, 6, 7 Large differences in SMM conditions included in different studies lead to incomparable SMM frequencies and an inability to benchmark population rates of SMM. The objectives of this study were to propose a comprehensive definition of SMM, to use the definition to create an empirically justified list of component SMM types and subtypes, and to use this list to examine SMM rates in Canada. The proposed definition of SMM, and its components, could serve to spur efforts towards creating an international consensus for SMM surveillance and for benchmarking maternal health outcomes in populations.

METHODS

Historical note

The Canadian Perinatal Surveillance System (CPSS) began monitoring SMM approximately 15 years ago,17, 18 using diagnosis and intervention codes (based on the International Classification of Diseases and Related Health Problems, 9th Revision (ICD‐9) and the Canadian Classification of Procedures) in hospitalisation data. The list of conditions that constituted SMM was revised in 2010 after a formal assessment of the diagnoses and procedures available in the Canadian version of the International Classification of Diseases and Related Health Problems, 10th Revision (ICD‐10CA) and the Canadian Classification of Health Interventions (CCI).19 However, even that list was flawed in some respects; one shortcoming was the exclusion of severe pre‐eclampsia and HELLP syndrome cases due to coding limitations in the early version of ICD‐10 CA. This problem was identified by the CPSS in 201019 and subsequently rectified by the Canadian Institute for Health Information; cases of severe pre‐eclampsia and HELLP syndrome can now be identified in Canadian hospitalisation data from 2012 onwards. Inclusion of conditions that did not necessarily represent SMM per se (eg asymptomatic HIV infection) and exclusion of some severe illnesses (eg surgical or manual correction of inverted uterus) were other limitations in the 2010 CPSS definition of composite SMM.

Definition of SMM

Severe maternal morbidity was defined as a set of heterogeneous maternal conditions known to be associated with severe illness and with prolonged hospitalisation or high case fatality. The definition was operationalised using an eclectic approach based on diagnostic, interventions and organ failure codes (see below).

List of SMM types and subtypes

The components of SMM were chosen through consensus by a multi‐disciplinary group of experts, who evaluated each candidate component in terms of feasibility of surveillance and validity (per the above‐mentioned definition of SMM). All SMM types and subtypes included in the 2010 list and others proposed for inclusion by the multi‐disciplinary group were evaluated in terms of frequencies, temporal trends, case fatality rates (ie death during the delivery admission), and (prolonged) length of hospital stay using hospitalisation data from Canada for the years 2006‐2015. The consensus assessments involved several meetings of the multi‐disciplinary group during which empirical data on each potential SMM type and subtype were reviewed, including the relevant code(s) in ICD‐10CA and CCI.

Data source

Information on these hospital deliveries (2006‐2015) was obtained from the Discharge Abstract Database of the Canadian Institute for Health Information, which contained records for approximately 98% of all deliveries in Canada (excluding Quebec). The database included information routinely abstracted from medical charts by trained personnel using standardised definitions and processes.20 Details regarding maternal and infant characteristics, labour and delivery events, and diagnoses and procedures were documented, with diagnoses coded using ICD‐10CA, and procedures coded using CCI. The validity of the information in the Discharge Abstract Database maternal and newborn records has been routinely assessed and shown to accurately reflect information contained in medical charts.21, 22

Components of SMM: SMM types and SMM subtypes

With SMM in any population defined as the frequency (incidence for new conditions, prevalence for pre‐existing ones) of heterogeneous maternal conditions known to be associated with severe illness, prolonged length of hospital stay, or high case fatality, we used diagnostic, intervention, and organ failure codes to identify eligible maternal diseases (eg eclampsia), interventions (eg hysterectomy), and conditions that signified organ failure (eg acute renal failure). Length of hospital stay was assessed using mean and median duration of hospital stay and the proportion of women with a prolonged length of hospital stay (≥7 days). Each candidate condition considered as signifying a potential SMM was evaluated by examining rates, temporal trends, length of stay, and case fatality rates for the years 2006‐2015 (with length of stay and case fatality contrasted among women with and without the candidate SMM). Once the SMM component (subtypes) list was finalised, the SMM subtypes were categorised for simplicity into SMM types based on aetiology, management, or other commonalities (eg the different forms of severe haemorrhage were grouped together, as were different surgical complications).

Descriptive epidemiology of SMM, Canada, 2012‐2016

This 2018 list of SMM conditions was then used to describe the epidemiology of SMM in Canada (excluding Quebec) for the years 2012‐2016. SMM rates were estimated as an overall composite, as well as broad SMM types, and individual SMM subtypes.

Statistical analysis

The frequencies of composite SMM, SMM types, and SMM subtypes were expressed using rates and 95% confidence intervals (CI). Case fatality rates and proportions of women with a prolonged hospital stay (≥7 days) were calculated similarly. Rates of composite SMM were estimated within categories of maternal age, parity, plurality, mode of delivery, and other factors, and contrasts between categories of a determinant were quantified using rate ratios and 95% confidence intervals. The population attributable fractions (PAF23) for prolonged hospital stay and maternal death associated with composite and specific SMM types/subtypes (or, in other words, the fraction of prolonged hospital stays and deaths that could be prevented by eliminating composite SMM or a specific SMM type/subtype) were estimated using the formula. where PAF denotes the population attributable fraction, p denotes the proportion of cases with prolonged hospitalisation/death due to composite SMM or a specific SMM type/subtype, and RR denotes the rate ratio contrasting the rate of prolonged hospitalisation or death among women with composite SMM or with a specific SMM type/subtype vs women without SMM or without that specific SMM type/subtype. Analysis was carried out using SAS version 9.1 (SAS Institute).

Ethics considerations

Privacy considerations required the suppression of cells with small values (1‐4); in such cases, rates were provided as ranges calculated using 1 and 4 as the numerator. Since the study was based on de‐identified data (and conducted under the surveillance mandate of the Public Health Agency of Canada), no ethics approval from an Institutional Review Board was sought.

RESULTS

There were 2 843 395 hospital deliveries in Canada (excluding Quebec) between 2006 and 2015. Table 1 shows selected conditions assessed for inclusion as SMM subtypes. The assessment resulted in a deletion of some SMM components from the previous 2010 list (eg women with asymptomatic HIV infection) and the addition of new SMM components (eg acute fatty liver with plasma or red cell transfusion). Several candidate conditions assessed for inclusion were not added to the list (eg type 1 diabetes and obesity). The 2018 list of SMM subtypes (and their categorisation into broad SMM types) is presented in Table 2. Tables and Figures providing details regarding the various conditions evaluated as candidates for SMM are provided in Table S1.
Table 1

Frequency, length of hospitalisation, and case fatality rates associated with overall severe maternal morbidity (SMM), and for selected SMM types and subtypes evaluated for the new 2018 list of SMM, Canada (excluding Quebec), 2006‐2015 (based on 2 843 395 hospital deliveries)

MorbidityNumberRate per 100 000 deliveriesCase fatality rate* Length of stay (days)
No. of deathsRate per 1000 deliveriesMean%≥7 d
No SMM (2010 list16)2 801 12898 513.5120.0042.31.1
At least one SMM (2010 list16)42 2671486.5982.325.211.8
SMM on 2010 list; deleted from 2018 list
HIV: asymptomatic infection or disease143450.4<50.70, 2.795.311.2
HIV: asymptomatic infection132046.400.05.211.0
Hypertensive heart/renal disease652.300.04.510.8
Evacuation of incisional haematoma66523.400.05.717.6
SMM on 2010 list; retained in 2018 list
Acute renal failure without dialysis84429.7910.710.645.1
Puerperal sepsis without ICU admission196969.200.06.75.6
Evacuation incisional haematoma and RBC transfusion1334.700.07.533.1
HIV disease1144.0<58.77, 35.15.813.2
Cardiomyopathy60521.3<51.65, 6.616.533.2
New SMM evaluated; added to 2018 list
Severe pre‐eclampsia 2927258.8<50.34, 1.376.333.0
HELLP syndrome 3124276.2<50.32, 1.285.322.4
Acute fatty liver and plasma/RBC transfusion2368.3521.29.733.5
Maternal intensive care unit admission5454191.85710.59.032.4
Maternal intensive care unit admission ≤ 24 hours225979.42712.05.916.3
Inversion of uterus (vaginal delivery)28910.2<53.46, 13.82.90.35
New SMM evaluated; not added to 2018 list
Uterine rupture2959104.1<50.34, 1.353.74.7
Acute fatty liver 12 505439.860.483.13.5
Malignant neoplasms103136.31211.65.615.8
Thyroid disorders21 034739.7<50.05, 0.193.24.8
Type 1 diabetes209873.800.05.921.2
Type 2 diabetes3220113.2<50.31, 1.244.212.8
Obesity38 3481348.7<50.03, 0.103.14.7

Abbreviations: RBC, red blood cells; ICU, intensive care unit.

If the numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of the actual value, and 95% interval estimates were not provided.

Based on hospitalisation data from 2012 to 2015.

The conditions under acute fatty liver (O26.6) were expanded in ICD‐10‐CA version 2009 to include ‘Cholestasis (intrahepatic) in pregnancy’ and ‘Obstetric cholestasis’.

Table 2

Severe maternal morbidity (SMM) types, subtypes, and International Classification of Diseases (ICD‐10CA) and Canadian Classification of Health Interventions (CCI) codes for each SMM subtype

SMM typeSMM subtypeICD‐10CA, CCI codes, and other variables
SPE, HELLP, eclampsiaSevere pre‐eclampsia, HELLP syndromeO14.1, O14.2
EclampsiaO15
Severe haemorrhagePlacenta praevia with haemorrhage and red cell transfusionO44.1 + RBCTRNSF = ‘Y’
Placental abruption with coagulation defectO45.0
Antepartum haemorrhage with coagulation defectO46.0
Intrapartum haemorrhage with coagulation defectO67.0
Intrapartum haemorrhage with red cell transfusionO67 + RBCTRNSF = ‘Y’
Postpartum haemorrhage with red cell transfusion, procedures to the uterus, or hysterectomy

O72 + any of the following:

RBCTRNSF = ‘Y’, or

(1.RM.13, 1.KT.51, 5.PC.91.LA, or 5.PC.91.HV) + RBCTRNSF = 1, or

(5.MD.60.RC, 5.MD.60.RD, 5.MD.60.KE, 5.MD.60.CB, or 1.RM.89.LA*), or

1.RM.87.LA‐GX

Curettage with red cell transfusion(5.PC.91.GA, 5.PC.91.GC, or 5.PC.91.GD) + RBCTRNSF = ‘Y’
Maternal ICU admissionMaternal ICU admissionFTSPCU in (‘10’,‘20’,‘25’,‘30’,‘35’,‘40’,‘45’,‘60’,‘80’)
Surgical complicationsComplications of obstetric surgery and proceduresO75.4
Evacuation of incisional haematoma with RBC transfusion5.PC.73.JS + RBCTRNSF = ‘Y’
Repair of bladder, urethra, or intestine5.PC.80.JR, 1.NK.80, or 1.NM.80
Reclosure of caesarean wound with RBC transfusion(5.PC.80.JM or 5.PC.80.JH) + RBCTRNSF = ‘Y’
HysterectomyCaesarean hysterectomy5.MD.60.RC, 5.MD.60.RD, 5.MD.60.KE, 5.MD.60.CB
Hysterectomy using an open approach (without bladder neck suspension, suspension of vaginal vault, or pelvic floor repair)1.RM.89.LA* (exclude if 1.PL.74, 1.RS.74, or 1.RS.80 code also present) or 1.RM.87.LA‐GX
 
SepsisPuerperal sepsisO85
Septicaemia during labourO75.3
Embolism, shock, DICObstetric shockO75.1, R57, T80.5, or T88.6
Obstetric embolismO88
Disseminated intravascular coagulationD65
Assisted ventilationAssisted ventilation through endotracheal tube1.GZ.31.CA‐ND
Assisted ventilation through tracheostomy1.GZ.31.CR‐ND
Cardiac complications of anaesthesiaO74.2, O89.1
Cardiac conditionsCardiac complications of anaesthesiaO74.2, O89.1
CardiomyopathyO90.3, I42, I43
Cardiac arrest and resuscitationI46, I49.0, 1.HZ.09, 1.HZ.30
Myocardial infarctionI21, I22
Pulmonary oedema and heart failureI50, J81
Acute renal failureAcute renal failureO90.4, N17, N19 or N99.0
Dialysis1.PZ.21
Severe uterine ruptureRupture of the uterus with red cell transfusion, procedures to the uterus, or hysterectomy(O71.0 or O71.1) + any of the following:

RBCTRNSF=‘Y’, or

(1.RM.13, 1.KT.51, 5.PC.91.LA, or 5.PC.91.HV) + RBCTRNSF=‘Y’, or

(5.MD.60.RC, 5.MD.60.RD, 5.MD.60.KE, 5.MD.60.CB, or 1.RM.89.LA*), or

1.RM.87.LA‐GX

Cerebrovascular accidentsCerebral venous thrombosis in pregnancyO22.5
Cerebral venous thrombosis in the puerperiumO87.3
Subarachnoid and intracranial haemorrhage, and cerebral infarctionI60, I61, I62, I63, or I64
Acute fatty liver with red cell transfusion or plasma transfusionO26.6 + (RBCTRNSF=‘Y’ or PLSTRNSF=’Y’)
Hepatic failureK71 or K72
Cerebral oedema or comaG93.6 or R40.2
Other typesPulmonary, cardiac, and CNS complications of anaesthesia during pregnancy, labour, delivery, or the puerperiumO29.0, O29.1, O29.2, O89.0, O89.1, O89.2, O74.0, O74.1, O74.2, or O74.3
Status asthmaticusJ45.01, J45.11, J45.81, or J45.91
Adult respiratory distress syndromeJ80
Acute abdomenK35, K37, K65, N73.3, or N73.5
Surgical or manual correction of inverted uterus for vaginal births only5.PC.91.HQ or 5.PC.91.HP, restricted to vaginal births (ie absence of caesarean code 5.MD.60)
Sickle cell anaemia with crisisD57.0
Acute psychosisF53.1 or F23
Status epilepticusG41
HIV diseaseB20‐24, O98.7

on selected diagnostic and procedure codes:

• Canadian Institute for Health Information coding specific to severe pre‐eclampsia and HELLP (O14.1 and O14.2) began in 2012. The conditions under acute fatty liver (O26.6) were expanded in ICD‐10‐CA version 2009, to add codes for the sixth digits of ‘2’ (Delivered, with mention of postpartum complication) and ‘4’ (Postpartum condition or complication). Previously postpartum liver disorders may have been captured at O90.802 and O90.804 Other complications of the puerperium, not elsewhere classified, respectively. In addition, in ICD‐10‐CA version 2009 the conditions included in this code were expanded to include ‘Cholestasis (intrahepatic) in pregnancy’ and ‘Obstetric cholestasis’. Previously, cholestasis in pregnancy would have been classified as O99.6 Diseases of the digestive system complicating pregnancy, childbirth and the puerperium which included conditions in K80‐K93, and more specifically, K83.1 Cholestasis NEC.

• The CCI code 5.PC.91.HV Interventions to uterus (following delivery or abortion), compression using intrauterine balloon was introduced in CCI version 2012. Previously, this intervention may have been captured by code 5.PC.91.HT Interventions to uterus (following delivery or abortion) uterine (and vaginal) packing.

1.RM.89.LA is included only if codes 1.PL.74, 1.RS.74, or 1.RS.80 are NOT also present.

Frequency, length of hospitalisation, and case fatality rates associated with overall severe maternal morbidity (SMM), and for selected SMM types and subtypes evaluated for the new 2018 list of SMM, Canada (excluding Quebec), 2006‐2015 (based on 2 843 395 hospital deliveries) Abbreviations: RBC, red blood cells; ICU, intensive care unit. If the numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of the actual value, and 95% interval estimates were not provided. Based on hospitalisation data from 2012 to 2015. The conditions under acute fatty liver (O26.6) were expanded in ICD‐10‐CA version 2009 to include ‘Cholestasis (intrahepatic) in pregnancy’ and ‘Obstetric cholestasis’. Severe maternal morbidity (SMM) types, subtypes, and International Classification of Diseases (ICD‐10CA) and Canadian Classification of Health Interventions (CCI) codes for each SMM subtype O72 + any of the following: RBCTRNSF = ‘Y’, or (1.RM.13, 1.KT.51, 5.PC.91.LA, or 5.PC.91.HV) + RBCTRNSF = 1, or (5.MD.60.RC, 5.MD.60.RD, 5.MD.60.KE, 5.MD.60.CB, or 1.RM.89.LA*), or 1.RM.87.LA‐GX RBCTRNSF=‘Y’, or (1.RM.13, 1.KT.51, 5.PC.91.LA, or 5.PC.91.HV) + RBCTRNSF=‘Y’, or (5.MD.60.RC, 5.MD.60.RD, 5.MD.60.KE, 5.MD.60.CB, or 1.RM.89.LA*), or 1.RM.87.LA‐GX on selected diagnostic and procedure codes: • Canadian Institute for Health Information coding specific to severe pre‐eclampsia and HELLP (O14.1 and O14.2) began in 2012. The conditions under acute fatty liver (O26.6) were expanded in ICD‐10‐CA version 2009, to add codes for the sixth digits of ‘2’ (Delivered, with mention of postpartum complication) and ‘4’ (Postpartum condition or complication). Previously postpartum liver disorders may have been captured at O90.802 and O90.804 Other complications of the puerperium, not elsewhere classified, respectively. In addition, in ICD‐10‐CA version 2009 the conditions included in this code were expanded to include ‘Cholestasis (intrahepatic) in pregnancy’ and ‘Obstetric cholestasis’. Previously, cholestasis in pregnancy would have been classified as O99.6 Diseases of the digestive system complicating pregnancy, childbirth and the puerperium which included conditions in K80‐K93, and more specifically, K83.1 Cholestasis NEC. • The CCI code 5.PC.91.HV Interventions to uterus (following delivery or abortion), compression using intrauterine balloon was introduced in CCI version 2012. Previously, this intervention may have been captured by code 5.PC.91.HT Interventions to uterus (following delivery or abortion) uterine (and vaginal) packing. 1.RM.89.LA is included only if codes 1.PL.74, 1.RS.74, or 1.RS.80 are NOT also present. Table 3 shows the frequency, case fatality rate, and length of hospital stay associated with overall (composite) SMM for the period 2012 to 2016 based on the 2018 definition. Among the 1,418,545 deliveries during this period, the 22 799 cases of SMM yielded a composite SMM rate of 16.1 (95% CI 15.9, 16.3) per 1000 deliveries. Case fatality rates among women with and without SMM were 2.0 and 0.004 per 1000 deliveries, respectively. The median lengths of hospital stay were 4.0 and 2.0 days, respectively, among women with and without a severe maternal morbidity, while the corresponding proportions of women with a prolonged length of stay were 18.8% and 1.3%.
Table 3

Frequency, case fatality, and length of hospital stay (LOS) for composite severe maternal morbidity (SMM) and SMM types under the 2018 SMM definition, Canada (excluding Quebec), 2012‐2016

SMM typeFrequencyCase fatalityLength of stay
Number of casesRate per 100 000 (95% CI)Number of deathsRate per 1000* (95% CI)Median (days)% with LOS ≥ 7 days
All deliveries1 418 545510.04 (0.03, 0.05)2.01.5
Any SMM22 7991607.2 (1586.6, 1628.0)462.0 (1.5, 2.7)4.018.8
No SMM1 395 74698 392.8 (98 3372.0, 98 413.4)50.004 (0.001, 0.009)2.01.3
Maternal ICU admission2729192.4 (185.2, 199.8)248.8 (5.9, 13.1)5.036.9
Severe pre‐eclampsia, HELLP, eclampsia7923558.5 (546.4, 570.9)<50.13, 0.50* 5.026.2
Severe haemorrhage7085499.5 (487.9, 511.2)192.7 (1.7, 4.2)3.014.2
Severe uterine rupture20414.4 (12.5, 16.5)<54.9, 19.6* 5.027.5
Hysterectomy2109148.7 (142.4, 155.2)62.8 (1.3, 6.1)3.022.6
Sepsis129691.4 (86.5, 96.5)<50.77, 3.09* 4.026.1
Embolism, shock, or DIC97368.6 (64.3, 73.0)1919.5 (12.5, 30.3)4.028.2
ARF or dialysis64745.6 (42.2, 49.3)913.9 (7.3, 26.2)7.053.0
Cardiac conditions88762.5 (58.5, 66.8)3640.6 (29.5, 55.7)5.034.9
Cerebrovascular accidents1369.6 (8.1, 11.4)536.8 (15.8, 83.2)3.027.9
Surgical complications2752194.0 (186.8, 201.4)186.5 (4.1, 10.3)3.013.1
Assisted ventilation94066.3 (62.1, 70.6)2930.9 (21.6, 44.0)6.047.8

Abbreviations: CI, confidence interval; ICU, intensive care unit; DIC, disseminated intravascular coagulation; ARF, acute renal failure.

If the numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of actual value (95% confidence interval not provided).

Frequency, case fatality, and length of hospital stay (LOS) for composite severe maternal morbidity (SMM) and SMM types under the 2018 SMM definition, Canada (excluding Quebec), 2012‐2016 Abbreviations: CI, confidence interval; ICU, intensive care unit; DIC, disseminated intravascular coagulation; ARF, acute renal failure. If the numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of actual value (95% confidence interval not provided). Rates of composite SMM were significantly higher among women aged 15‐19 years, 35‐39 years, and ≥40 years, being 18.8, 19.2, and 30.2 per 1000 deliveries, respectively, compared with 15.0 per 1000 deliveries among women aged 20‐24 years Table 4. SMM rates were also significantly higher among nulliparous women,women with increasing parity, multi‐fetal pregnancy, or previous caesarean delivery; and among women with labour induction or caesarean delivery. Women who received epidural anaesthesia had lower rates of composite SMM than those who did not (12.5 vs 19.0 per 1000 deliveries).
Table 4

Numbers and rates of women with severe maternal morbidity by maternal and clinical characteristics, Canada (excluding Quebec), 2012‐2016

Maternal characteristicsNumber of deliveriesSevere maternal morbidity
NumberRate per 10 000 deliveries (95% CI)Rate Ratio (95% CI)
Age (years)
<153075162.9 (53.1, 376.0)1.09 (0.46, 2.60)
15‐1943 862824187.9 (175.4, 201.0)1.25 (1.16, 1.35)
20‐24184 0642757149.8 (144.3, 155.4)1.00 (Reference)
25‐29403 6955592138.5 (134.9, 142.2)0.92 (0.88, 0.97)
30‐34491 6687395150.4 (147.0, 153.8)1.00 (0.96, 1.05)
35‐39242 5264644191.5 (186.1, 197.0)1.28 (1.22, 1.34)
≥4052 4231582301.8 (287.3, 316.8)2.01 (1.90, 2.14)
Parity
0491 9319819199.6 (195.7, 203.6)1.67 (1.62, 1.73)
1388 5034636119.3 (115.9, 122.8)1.00 (Reference)
2154 8942112136.4 (130.6, 142.3)1.14 (1.09, 1.20)
354 132845156.1 (145.8, 166.9)1.31 (1.22, 1.41)
419 904355178.4 (160.4, 197.7)1.49 (1.34, 1.66)
≥518 252366200.5 (180.7, 221.9)1.68 (1.51, 1.87)
Missing290 9294666160.4 (155.8, 165.0)1.34 (1.29, 1.40)
Elderly primigravida
Yes17 189577335.7 (309.3, 363.7)2.12 (1.95, 2.30)
No1 401 35622 222158.6 (156.5, 160.7)1.00 (Reference)
Previous caesarean delivery
Yes199 8294264213.4 (207.1, 219.8)1.40 (1.36, 1.45)
No1 218 71618 535152.1 (149.9, 154.3)1.00 (Reference)
Epidural anaesthesia
Yes640 1868029125.4 (122.7, 128.2)0.66 (0.64, 0.68)
No778 35914 770189.8 (186.7, 192.8)1.00 (Reference)
Labour induction
Yes370 1757714208.4 (203.8, 213.0)1.45 (1.41, 1.49)
No1 048 37015 085143.9 (141.6, 146.2)1.00 (Reference)
Caesarean delivery
Yes404 31913 744339.9 (334.4, 345.6)3.81 (3.71, 3.91)
No1 014 226905589.3 (87.5, 91.1)1.00 (Reference)
Plurality
Singleton1 394 77521 402153.4 (151.4, 155.5)1.00 (Reference)
Twin23 3261348577.9 (548.3, 608.6)3.77 (3.57, 3.97)
Triplet or higher‐order443481083.5 (809.8, 1410.8)7.06 (5.40, 9.23)
Total1 418 54522 79916.1 (15.9, 16.3)
Numbers and rates of women with severe maternal morbidity by maternal and clinical characteristics, Canada (excluding Quebec), 2012‐2016 The frequency, case fatality rates, and length of stay for broad types of SMM are shown in Table 3 (SMM types are not mutually exclusive). The most common types of SMM included severe pre‐eclampsia, eclampsia, and HELLP syndrome,severe haemorrhage; surgical complications; maternal intensive care unit admission; and hysterectomy. Table 5 provides the same details for each SMM subtype (SMM subtypes are not mutually exclusive). Severe pre‐eclampsia and HELLP syndrome (514.6 per 100 000 deliveries), postpartum haemorrhage with red cell transfusion, procedures to the uterus or hysterectomy (433.2 per 100 000), maternal intensive care unit admission (192.4 per 100 000), hysterectomy (148.7 per 100 000), and complications of surgery and procedures (106.9 per 100 000) were the most common SMM subtypes.
Table 5

Severe maternal morbidity (SMM) subtypes and associated case fatality and length of hospital stay (LOS), Canada (excluding Quebec), 2012‐2016 (based on 1 418 545 hospital deliveries)

SMM subtypesNumber of SMM casesRate per 100 000 (95% CI)Case fatality rate/1000Median LOS (days)% with LOS ≥ 7 d*
Severe pre‐eclampsia or HELLP syndrome7300514.6 (502.9, 526.5)0.14, 0.55* 5.026.9
Eclampsia66847.1 (43.5, 50.8)0.04.019.5
Cerebral venous thrombosis in pregnancy352.5 (1.7, 3.5)0.02.02.8, 11.4*
Cerebral venous thrombosis in the puerperium60.4 (0.1, 0.9)0.020.516.7, 66.7*
Cerebrovascular accidents–stroke986.9 (5.6, 8.4)51.04.036.7
Placenta praevia with haemorrhage and RBC transfusion53137.4 (34.3, 40.7)1.9, 7.5* 5.044.6
Placental abruption with coagulation defect27519.4 (17.2, 21.8)3.6, 14.5* 3.016.7
Antepartum haemorrhage with coagulation defect795.6 (4.4, 7.0)12.7, 50.6* 3.016.5
Intrapartum haemorrhage with coagulation defect1077.5 (6.2, 9.1)9.3, 37.4* 4.021.5
Intrapartum haemorrhage with RBC transfusion35224.8 (22.2, 27.5)2.8, 11.4* 4.019.3
Postpartum haemorrhage with RBC transfusion, procedures to the uterus, or hysterectomy6145433.2 (422.4, 444.2)2.43.013.1
Curettage with RBC transfusion93465.8 (61.7, 70.2)1.1, 4.3* 3.07.1
Rupture of the uterus with RBC transfusion or procedures to the uterus or hysterectomy20414.4 (12.5, 16.5)4.9, 19.6* 5.027.5
Cardiac conditions88762.5 (58.5, 66.8)40.65.034.9
Cardiac complications of anaesthesia563.9 (3.0, 5.1)17.9, 71.4* 3.01.8, 7.1*
Cardiomyopathy35224.8 (22.2, 27.5)2.8, 11.4* 3.026.4
Cardiac arrest and resuscitation1419.9 (8.3, 11.7)241.14.032.0
Myocardial infarction130.9 (0.5, 1.5)06.038.5
Pulmonary oedema and heart failure41028.9 (26.2, 31.8)2.4, 9.8* 9.049.8
Septicaemia during labour30221.3 (18.9, 23.8)3.3, 13.2* 3.012.9
Puerperal sepsis99770.3 (66.0, 74.8)1.0, 4.0* 5.030.1
Obstetric shock48634.3 (31.3, 37.5)28.84.030.3
Obstetric embolism42229.7 (27.0, 32.8)16.64.024.4

Abbreviations: CI, confidence interval; CNS, central nervous system; RBCT, red blood cell transfusion.

If numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of the actual value.

Severe maternal morbidity (SMM) subtypes and associated case fatality and length of hospital stay (LOS), Canada (excluding Quebec), 2012‐2016 (based on 1 418 545 hospital deliveries) Abbreviations: CI, confidence interval; CNS, central nervous system; RBCT, red blood cell transfusion. If numerator of the rate was >0 and <5, a range was provided (assuming a numerator of 1 and 4) instead of the actual value. Case fatality rates were highest among women with cardiac arrest and resuscitation (241.1 per 1000), hepatic failure (147.1 per 1000), and dialysis (67.6 per 1000), and among those with cerebrovascular accidents (51.0 per 1000). Women with several different SMM subtypes had an extended hospital stay, with ≥40% having a hospital stay ≥7 days among those with placenta praevia requiring blood transfusion, pulmonary oedema and heart failure, disseminated intravascular coagulation, acute renal failure/dialysis, evacuation of incisional haematoma requiring transfusion, acute fatty liver requiring transfusion, assisted ventilation, or sickle cell anaemia with crisis Table 5. Rate ratios and PAFs for each SMM type are presented in Table 6. The rate ratio for a prolonged hospital stay among women with any SMM (vs those without) was 14.5, while the rate ratio for prolonged hospital stay among women admitted to an ICU (vs those not admitted to an ICU) was 24.4. The rate ratio for maternal death among women with any severe maternal morbidity (vs those without) was 459.1, and among those admitted to ICU (vs those not admitted to ICU), the rate ratio for death was 461.7. The PAF for maternal death associated with any SMM was 88.0% (95% CI 74.6, 94.4), while that associated with maternal ICU admission was 47.0% (95% CI 31.3, 59.1). Thus, preventing all SMM cases (per the 2018 SMM definition) would eliminate 88% of maternal deaths, while preventing SMM resulting in maternal ICU admission would eliminate 47% of maternal deaths. The PAF for prolonged hospital stay associated with any SMM was 17.8% (95% CI 17.3, 18.3), while the PAF for prolonged hospital stay associated with maternal ICU admission was 4.3% (95% CI 4.0, 4.6).
Table 6

Frequencies of specific severe maternal morbidity (SMM) types, and associated rate ratios and population attributable fractions (PAF) for case fatality and prolonged length of hospital stay (LOS), Canada (excluding Quebec), 2012‐2016

MorbidityProlonged LOSCase fatality
Rate ratio (95% CI)PAF (95% CI)Rate ratio (95% CI)PAF (95% CI)
Any severe maternal morbidity14.5 (14.0, 14.9)17.8 (17.3, 18.3)459.1 (195.9, 1076.0)88.0 (74.6, 94.4)
Severe pre‐eclampsia, HELLP, eclampsia18.1 (17.5, 18.9)8.75 (8.36, 9.13)3.6, 15.2* 1.8, 5.4*
Cerebrovascular accident17.7 (13.5, 23.2)0.16 (0.11, 0.20)1133.6 (457.5, 2809.3)9.8 (1.3, 17.6)
Severe haemorrhage9.36 (8.82, 9.92)4.01 (3.73, 4.28)118.3 (67.1, 208.6)37.2 (22.1, 49.0)
Severe uterine rupture17.4 (13.9, 21.8)0.24 (0.17, 0.30)139.1, 591.7* 2.0, 7.8*
Cardiac conditions22.4 (20.5, 24.5)1.32 (1.17, 1.47)3835.8 (2107.8, 6980.4)70.6 (55.0, 80.8)
Sepsis16.7 (15.3 18.4)1.42 (1.26, 1.58)21.9, 93.1* 1.9, 7.8*
Obstetric embolism, shock, DIC18.0 (16.3, 19.9)1.15 (1.01, 1.30)865.0 (492.1, 1520.7)37.2 (22.4, 49.2)
Acute renal failure/dialysis34.0 (31.6, 36.6)1.48 (1.32, 1.65)469.6 (229.5, 960.7)17.6 (6.44, 27.4)
Hysterectomy14.6 (13.5, 15.8)1.98 (1.79, 2.17)89.5 (38.2, 209.7)11.4 (2.32, 20.1)
Surgical complications8.42 (7.64, 9.27)1.42 (1.25, 1.58)280.6 (158.2, 497.7)34.9 (20.6, 47.6)
Maternal ICU admission24.4 (23.2, 25.7)4.31 (4.03, 4.58)461.2 (266.4, 798.2)47.0 (31.3, 59.1)
Assisted ventilation30.8 (28.8, 33.0)1.94 (1.75, 2.12)1987.9 (1146.4, 3447.1)56.9 (40.8, 68.5)

Rate ratios contrast the rate of prolonged hospitalisation/death among women with any severe morbidity vs women without severe morbidity (and the presence of specific SMM types with the absence of that SMM type). The population attributable fraction expresses the fraction of women with a prolonged hospital stay/death that could be eliminated by preventing all SMM or by preventing a specific SMM type. Note: SMM types are not mutually exclusive.

Abbreviation: DIC, disseminated intravascular coagulation.

If the numerator of the rate was >0 and <5, a numerator of 1 and 4 was used to calculate the rate and 2 rate ratios and PAFs were estimated (95% CI not provided).

Frequencies of specific severe maternal morbidity (SMM) types, and associated rate ratios and population attributable fractions (PAF) for case fatality and prolonged length of hospital stay (LOS), Canada (excluding Quebec), 2012‐2016 Rate ratios contrast the rate of prolonged hospitalisation/death among women with any severe morbidity vs women without severe morbidity (and the presence of specific SMM types with the absence of that SMM type). The population attributable fraction expresses the fraction of women with a prolonged hospital stay/death that could be eliminated by preventing all SMM or by preventing a specific SMM type. Note: SMM types are not mutually exclusive. Abbreviation: DIC, disseminated intravascular coagulation. If the numerator of the rate was >0 and <5, a numerator of 1 and 4 was used to calculate the rate and 2 rate ratios and PAFs were estimated (95% CI not provided).

COMMENT

Principal findings

We used a priori knowledge and empirical support from frequencies, temporal trends, case fatality rates, and length of hospital stay to derive a list of conditions for SMM surveillance. The rate of composite SMM according to the revised list was 16.1 per 1000 deliveries in Canada, 2012‐2016. This rate was substantially higher among older women, primiparous women, women with high parity, multi‐fetal pregnancy, previous caesarean delivery, and women who had labour induction or a caesarean delivery. The most common SMM subtypes were severe pre‐eclampsia and HELLP syndrome, severe postpartum haemorrhage (ie postpartum haemorrhage requiring red cell transfusion, procedures to the uterus or hysterectomy), maternal intensive care unit admission, hysterectomy, and complications of surgery and procedures. Case fatality rates were highest among women with cardiac arrest and resuscitation, hepatic failure, those receiving dialysis, those with cerebrovascular accidents, and those with cardiac conditions. SMM was associated with a PAF of 47% to 18 %for prolonged hospitalisation and a PAF of 88% for maternal death.

Strengths of the study

The strengths of our study and the proposed SMM surveillance framework include reliance on multi‐disciplinary input and evidentiary support from contemporary data on deliveries. The hospitalisation data source (viz., the Discharge Abstract Database of the Canadian Institute for Health Information) has made changes in ICD‐10CA coding (eg introduction of a code for severe pre‐eclampsia in 2012) and other important aspects of data collection (linked mother and infant records, extraction of gestational age at delivery, etc), which have facilitated comprehensive monitoring of SMM.

Limitations of the data

Limitations of our study include an inability to identify some clinically relevant cases based on ICD‐10CA codes (eg extreme obesity) and to distinguish between some pre‐existing and acute complications arising in pregnancy. We were unable to identify women who received more than one transfusion (a measure of more severe morbidity than haemorrhage with any transfusion), as our data source documented the type of blood component transfused but not the number of units. Collection of information on the number of pints of blood transfused would enable more accurate specification of haemorrhage severity and organ failure, and improved maternal health surveillance. Although overall SMM had a PAF of 88% for maternal death, the sum of the PAFs of the 12 individual SMM types exceeded 100%. This was expected, as the SMM types overlapped, both as illness entities and potentially as component causes of a sufficient cause(s) model of maternal death (or prolonged hospitalisation). Finally, our inability to include information from the province of Quebec (which did not contribute to the Discharge Abstract Database) was another limitation of our study.

Interpretation

Conditions included as components of severe maternal morbidity vary considerably in the literature.3, 4, 5, 6, 7, 24, 25, 26, 27 For instance, Euro‐Peristat (a part of the European Union's Health Monitoring Program) defined SMM as a composite of eclampsia, hysterectomy for postpartum haemorrhage, ICU admission, blood transfusion, or uterine artery embolisation.24 On the other hand, the EPIMOMS study group in France defined severe maternal morbidity to include the EURO‐PERISTAT indicators, as well as measures of organ system dysfunction (a total of 17 items).25 Such differences are at least partly due to a failure to formally define SMM per se (ie without reference to its component conditions) and instead rely on a selected list of SMM conditions chosen without specification as to criteria for inclusion and exclusion of candidate conditions. Our definition of SMM, which was based on a priori knowledge of illness severity and empirical assessments of prolonged hospitalisation and case fatality, ensured a high PAF for maternal death. More restrictive definitions, such as the EURO‐PERISTAT definition, which are focussed on direct obstetric morbidity, may not capture SMM due to cardiac conditions, surgical morbidity, and other complications which contribute substantially to prolonged hospitalisation and case fatality (Table 3). Published studies of population rates of SMM fall into three primary types, which differ based on the conceptual framework used for SMM surveillance. The EURO‐PERISTAT framework is based on the premise that surveillance of SMM can be restricted to key conditions that are feasible to assess in a valid manner. On the other hand, the WHO proposal for surveillance of maternal near‐miss (ie severe acute maternal morbidity) recommends the prospective follow‐up of severe maternal complications (ie potentially life‐threatening conditions) with a view to accurately and comprehensively identifying cases of organ system failure.28, 29 Some studies attempting to use the latter framework for near‐miss surveillance have documented underestimation of rates of SMM and maternal death both in high‐income and in low‐income settings.30, 31 This is partly because such studies30, 31 have typically employed retrospective assessments of organ system failure. However, prospective follow‐up of all potentially life‐threatening conditions is challenging even in high‐income settings. Our study describes the third type of SMM surveillance framework previously used by countries such as Australia, Canada, England, and the United States.5, 6, 7, 17, 18, 19, 25, 27, 32 This third framework employs a retrospective design and an eclectic approach (using disease‐based, intervention‐based, and organ system failure‐based criteria) to identify cases of SMM in routine hospitalisation data that include diagnosis, intervention codes, and other information. The list of SMM types and subtypes used in our study was similar, although perhaps more comprehensive than the maternal morbidity outcome indicator created by Roberts et al who identified ‘true’ severe maternal morbidity by examining the medical records of 400 cases of suspected severe morbidity and 800 non‐cases.32 In the Roberts et al study, three clinicians reviewed the medical records, identified SMM based on a clinical gestalt, and created a list of 11 morbid conditions and 15 procedures. We defined SMM to include severe maternal illnesses associated with prolonged length of hospital stay or high case fatality. Thus, conditions such as severe pre‐eclampsia, HELLP syndrome, and eclampsia constituted an SMM, since 26% of women with these conditions had a prolonged LOS. Conversely, 74% of such women did not have a prolonged LOS, but this was not a repudiation of the definition. Also, women with such severe illnesses and a LOS <  7 days were included as cases of SMM as it is possible to be severely ill, receive life‐saving intervention, and recover fairly quickly. We faced some challenges, however, in translating our SMM definition into an operational list of severely morbid conditions. One limitation arose from our reliance on ICD‐10CA codes, which do not capture all conditions of interest with sufficient accuracy. Extreme obesity, a maternal condition which could potentially satisfy our definition of SMM, is an example: ICD‐10CA includes a code for obesity but not extreme obesity. Additionally, obesity, which did not satisfy the SMM definition in terms of case fatality rates and prolonged length of stay, was captured in only a small fraction of women: less than 2% vs an expected frequency of over 10%.10, 33 We omitted conditions such as malignancy in pregnancy, which were associated with prolonged length of stay and high case fatality, from the SMM list because the associated burden of illness appeared to be mostly unrelated to pregnancy, and we were unable to identify cases in which the course of the malignancy was aggravated by pregnancy. On the other hand, we included conditions such as maternal ICU admission, which did not identify any additional deaths but did carry a high risk of prolonged length of stay.34 Finally, we encountered a few conditions (eg diabetes mellitus, asymptomatic HIV infection) where the prolonged length of hospital stay was likely associated with management or socio‐economic issues rather than severe morbidity per se. The rate ratios and PAFs associated with specific types of SMM in our study can be used to inform clinical practice and public health policy. From a public health standpoint, PAFs for maternal death show that cardiac conditions, haemorrhage, obstetric embolism, obstetric shock, DIC, and surgical complications are the priorities to be addressed in terms of SMM prevention. A substantial reduction in maternal mortality would likely result from a reduction in these SMM. Adverse temporal trends or geographic differences identified in our study also provide an impetus for action, whether nationally or at the provincial level. Audit of maternal deaths and SMM cases is a worthwhile undertaking that is being increasingly discussed in clinical circles, and such activities could help focus attention on prevention of SMM and maternal death through improved care.

Conclusions

We combined a priori clinical knowledge, prolonged length of stay, high case fatality, and expert consensus to identify a set of severely morbid conditions that could enable robust surveillance of SMM in Canada and other high‐income countries. These SMM subtypes, which vary in frequency, case fatality, and PAFs for maternal death, suggest that significant reductions in maternal mortality will result from the prevention or improved care of SMM, especially cardiac conditions, severe haemorrhage, obstetric embolism, obstetric shock, DIC, and surgical complications. Our 2018 list of SMM types and subtypes should help improve surveillance and benchmarking of SMM in Canada and elsewhere. Click here for additional data file.
  30 in total

1.  Severe maternal morbidity in Canada, 1991-2001.

Authors:  Shi Wu Wen; Ling Huang; Robert Liston; Maureen Heaman; Tom Baskett; I D Rusen; K S Joseph; Michael S Kramer
Journal:  CMAJ       Date:  2005-09-27       Impact factor: 8.262

2.  Changes in maternal characteristics in Nova Scotia, Canada from 1988 to 2001.

Authors:  Deshayne B Fell; K S Joseph; Linda Dodds; Alexander C Allen; Krista Jangaard; Michiel Van den Hof
Journal:  Can J Public Health       Date:  2005 May-Jun

3.  Validation of perinatal data in the Discharge Abstract Database of the Canadian Institute for Health Information.

Authors:  K S Joseph; J Fahey
Journal:  Chronic Dis Can       Date:  2009

4.  Severe maternal morbidity among delivery and postpartum hospitalizations in the United States.

Authors:  William M Callaghan; Andreea A Creanga; Elena V Kuklina
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

5.  Preventing Maternal Morbidity from Obstetric Hemorrhage: Implications of a Provider Training Initiative.

Authors:  Michelle A Kominiarek; Shirley Scott; Abigail R Koch; Maripat Zeschke; Yvette Cordova; Samadh F Ravangard; Deborah Schy; Stacie E Geller
Journal:  Am J Perinatol       Date:  2016-05-30       Impact factor: 1.862

6.  Validating the British Columbia Perinatal Data Registry: a chart re-abstraction study.

Authors:  Gillian Frosst; Jennifer Hutcheon; K S Joseph; Brooke Kinniburgh; Cathe Johnson; Lily Lee
Journal:  BMC Pregnancy Childbirth       Date:  2015-05-27       Impact factor: 3.007

7.  Validating the WHO maternal near miss tool: comparing high- and low-resource settings.

Authors:  Tom Witteveen; Hans Bezstarosti; Ilona de Koning; Ellen Nelissen; Kitty W Bloemenkamp; Jos van Roosmalen; Thomas van den Akker
Journal:  BMC Pregnancy Childbirth       Date:  2017-06-19       Impact factor: 3.007

Review 8.  A global view of severe maternal morbidity: moving beyond maternal mortality.

Authors:  Stacie E Geller; Abigail R Koch; Caitlin E Garland; E Jane MacDonald; Francesca Storey; Beverley Lawton
Journal:  Reprod Health       Date:  2018-06-22       Impact factor: 3.223

9.  What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe.

Authors:  M-H Bouvier-Colle; A D Mohangoo; M Gissler; Z Novak-Antolic; C Vutuc; K Szamotulska; J Zeitlin
Journal:  BJOG       Date:  2012-06       Impact factor: 6.531

10.  WHO systematic review of maternal morbidity and mortality: the prevalence of severe acute maternal morbidity (near miss).

Authors:  Lale Say; Robert C Pattinson; A Metin Gülmezoglu
Journal:  Reprod Health       Date:  2004-08-17       Impact factor: 3.223

View more
  9 in total

1.  Ways Forward in Preventing Severe Maternal Morbidity and Maternal Health Inequities: Conceptual Frameworks, Definitions, and Data, from a Population Health Perspective.

Authors:  Suzan L Carmichael; Barbara Abrams; Alison El Ayadi; Henry C Lee; Can Liu; Deirdre J Lyell; Audrey Lyndon; Elliott K Main; Mahasin Mujahid; Lu Tian; Jonathan M Snowden
Journal:  Womens Health Issues       Date:  2021-12-28

2.  Challenges in the Triage Care of Low-Risk Laboring Patients: A Comparison of 2 Models of Practice.

Authors:  Rachel Blankstein Breman; Julia C Phillippi; Ellen Tilden; Julie Paul; Erik Barr; Nicole Carlson
Journal:  J Perinat Neonatal Nurs       Date:  2021 Apr-Jun 01       Impact factor: 2.522

3.  Risk of severe maternal morbidity or death in relation to elevated hemoglobin A1c preconception, and in early pregnancy: A population-based cohort study.

Authors:  Alexander J F Davidson; Alison L Park; Howard Berger; Kazuyoshi Aoyama; Ziv Harel; Jocelynn L Cook; Joel G Ray
Journal:  PLoS Med       Date:  2020-05-19       Impact factor: 11.069

4.  Severe maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged hospitalisation and death.

Authors:  Susie Dzakpasu; Paromita Deb-Rinker; Laura Arbour; Elizabeth K Darling; Michael S Kramer; Shiliang Liu; Wei Luo; Phil A Murphy; Chantal Nelson; Joel G Ray; Heather Scott; Michiel VandenHof; K S Joseph
Journal:  Paediatr Perinat Epidemiol       Date:  2019-08-12       Impact factor: 3.980

5.  The Prevalence and Risk Factors for Severe Maternal Morbidities: A Systematic Review and Meta-Analysis.

Authors:  Nik Hussain Nik Hazlina; Mohd Noor Norhayati; Ismail Shaiful Bahari; Halilul Rahman Mohamed Kamil
Journal:  Front Med (Lausanne)       Date:  2022-03-17

6.  Preeclampsia and Severe Maternal Morbidity During the COVID-19 Pandemic: A Population-Based Cohort Study in Ontario, Canada.

Authors:  John W Snelgrove; Andrea N Simpson; Rinku Sutradhar; Karl Everett; Ning Liu; Nancy N Baxter
Journal:  J Obstet Gynaecol Can       Date:  2022-04-05

7.  Prepregnancy Emergency Department Use and Risks of Severe Maternal and Neonatal Morbidity in Canada.

Authors:  Catherine E Varner; Alison L Park; Joel G Ray
Journal:  JAMA Netw Open       Date:  2022-09-01

8.  Severe maternal morbidity in Scotland.

Authors:  J A Masterson; I Adamestam; M Beatty; J P Boardman; P Johnston; J Joss; H Lawrence; K Litchfield; T S Walsh; A Wise; R Wood; C J Weir; F C Denison; N I Lone
Journal:  Anaesthesia       Date:  2022-07-12       Impact factor: 12.893

9.  Feasibility of establishing a Canadian Obstetric Survey System (CanOSS) for severe maternal morbidity: a study protocol.

Authors:  Rohan D'Souza; Rebecca J Seymour; Marian Knight; Susie Dzakpasu; K S Joseph; Sara Thorne; Maria B Ospina; Jon Barrett; Jocelynn Cook; Deshayne B Fell; Heather Scott; Amy Metcalfe; Thomas van den Akker; Stephen Lapinsky; Leslie Skeith; Beth Murray-Davis; Prakesh Shah; Milena Forte; Rizwana Ashraf; Josie Chundamala; Sarah A Hutchinson; Kenneth K Chen; Isabelle Malhamé
Journal:  BMJ Open       Date:  2022-03-23       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.